The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study

• Published in: Journal of neuro-oncology 2020, Vol.146 (1), p.181-193
• Main Authors: Martins, Filipe, Schiappacasse, Luis, Levivier, Marc, Tuleasca, Constantin, Cuendet, Michel A., Aedo-Lopez, Veronica, Gautron Moura, Bianca, Homicsko, Krisztian, Bettini, Adrienne, Berthod, Gregoire, Gérard, Camille L., Wicky, Alexandre, Bourhis, Jean, Michielin, Olivier
• Format: Article
• Language: English
• Subjects: Brain cancer; Clinical Study; CTLA-4 protein; Immune checkpoint inhibitors; Immunotherapy; L-Lactate dehydrogenase; Lactic acid; Medical prognosis; Medicine; Medicine & Public Health; MEK inhibitors; Melanoma; Metastases; Metastasis; Monoclonal antibodies; Neurology; Oncology; PD-1 protein; Radiosurgery; Survival
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-019-03363-0

Background Evidence pointing to a synergistic effect of stereotactic radiosurgery (SRS) with concurrent immunotherapy or targeted therapy in patients with melanoma brain metastases (BM) is increasing. We aimed to analyze the effect on overall survival (OS) of immune checkpoint inhibitors (ICI) or BRAF/MEK inhibitors initiated during the 9 weeks before or after SRS. We also evaluated the prognostic value of patients’ and disease characteristics as predictors of OS in patients treated with SRS. Methods We identified patients with BM from cutaneous or unknown primary origin melanoma treated with SRS between 2011 and 2018. Results We included 84 patients. The median OS was 12 months (95% CI 9–20 months). The median follow-up was 30 months (95% CI 28–49). Twenty-eight patients with newly diagnosed BM initiated anti-PD-1 +/−CTLA-4 therapy (n = 18), ipilimumab monotherapy (n = 10) or BRAF+/- MEK inhibitors (n = 11), during the 9 weeks before or after SRS. Patients who received anti-PD-1 +/−CTLA-4 mAb showed an improved survival in comparison to ipilimumab monotherapy (OS 24 vs. 7.5 months; HR 0.32, 95% 0.12–0.83, p = 0.02) and BRAF +/−MEK inhibitors (OS 24 vs. 7 months, respectively; HR 0.11, 95% 0.04–0.34, p = 0.0001). This benefit remained significant when compared to the subgroup of patients treated with dual BRAF/MEK inhibition (BMi) (n = 5). In a multivariate Cox regression analysis an age > 65, synchronous BM, > 2 metastatic sites, > 4 BM, and an ECOG > 1 were correlated with poorer prognosis. A treatment with anti-PD-1+/−CTLA-4 mAbs within 9 weeks of SRS was associated with better outcomes. The presence of serum lactate dehydrogenase (LDH) levels ≥ 2xULN at BM diagnosis was associated with lower OS (HR 1.60, 95% CI 1.03–2.50; p = 0.04). Conclusions The concurrent administration of anti-PD-1+/−CTLA-4 mAbs with SRS was associated with improved survival in melanoma patients with newly diagnosed BM. In addition to CNS tumor burden, the extension of systemic disease retains its prognostic value in patients treated with SRS. Elevated serum LDH levels are predictors of poor outcome in these patients.